Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

  1. Ravassa, S.
  2. López, B.
  3. Ferreira, J.P.
  4. Girerd, N.
  5. Bozec, E.
  6. Pellicori, P.
  7. Mariottoni, B.
  8. Cosmi, F.
  9. Hazebroek, M.
  10. Verdonschot, J.A.J.
  11. Cuthbert, J.
  12. Petutschnigg, J.
  13. Moreno, M.U.
  14. Heymans, S.
  15. Staessen, J.A.
  16. Pieske, B.
  17. Edelmann, F.
  18. Clark, A.L.
  19. Cleland, J.G.F.
  20. Zannad, F.
  21. Díez, J.
  22. González, A.
Revue:
European Journal of Heart Failure

ISSN: 1879-0844,  1388-9842

Année de publication: 2022

Volumen: 24

Número: 2

Pages: 321-331

Type: Article

DOI: 10.1002/EJHF.2394 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus